Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Aug;28(4):580-590.
doi: 10.1111/1744-9987.14123. Epub 2024 Mar 12.

Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

Masanori Kato  1 , Hidetoshi Ito  1 , Akane Yamakawa  2 , Tatsuo Kagimura  2 , Masafumi Fukagawa  3 , Masahiro Yamamoto  1 , Yoshinori Saito  1 , Tadao Akizawa  4 , Hiroaki Ogata  1   5
Affiliations
Randomized Controlled Trial

Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

Masanori Kato et al. Ther Apher Dial. 2024 Aug.

Abstract

Introduction: The clinical benefits of aspirin in patients undergoing hemodialysis remain unclear.

Methods: The secondary analysis of the LANDMARK trial investigated whether aspirin use was associated with cardiovascular events (CVEs) and all-cause mortality was performed. A total of 2135 patients at risk for vascular calcification were analyzed using a Cox proportional hazards model with propensity score matching.

Results: The risk of CVEs was comparable between participants with aspirin use at baseline and those without at baseline, between participants with aspirin use during the study period and those without during the study period, and between participants with new aspirin prescription and those without aspirin use during the study period.

Conclusion: Aspirin use was not significantly associated with a lower risk of CVEs in participants undergoing hemodialysis patients at risk of vascular calcification.

Keywords: all‐cause death; aspirin; cardiovascular event; hemodialysis.

PubMed Disclaimer

References

REFERENCES

    1. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet. 2016;388(10041):276–284.
    1. Ogata H, Sugawara H, Yamamoto M, Ito H. Phosphate and coronary artery disease in patients with chronic kidney disease. J Atheroscler Thromb. 2024;31(1):1–14.
    1. Gregg LP, Hedayati SS. Management of traditional cardiovascular risk factors in CKD: What are the data? Am J Kidney Dis. 2018;72(5):728–744.
    1. Ethier J, Bragg‐Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, et al. Aspirin prescription and outcomes in hemodialysis patients: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2007;50(4):602–611.
    1. Hasegawa T, Elder SJ, Bragg‐Gresham JL, Pisoni RL, Yamazaki S, Akizawa T, et al. Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol. 2008;3(5):1373–1378.

Publication types

LinkOut - more resources